ReactArray Partners with MRSP
News Feb 15, 2006
ReactArray systems have been developed in collaboration with the pharmaceutical industry to facilitate high throughput reaction screening and optimisation.
MRSP will use its specialised knowledge of the pharmaceutical and speciality chemical markets to support ReactArray and its existing dealer network, accelerating awareness and market uptake of this product suite.
MRSP CEO, Dr. Thomas Schwalbe commented, "We are very pleased to work with ReactArray as it gives us the opportunity to provide best-in-class robotic batch technology to our existing customers."
"Recent extensions to the product suite enable drug stressing, solubility testing and chemical synthesis applications that will be particularly welcomed by chemists world wide."
"The new Solo product will boost the productivity of those process chemistry groups that have been waiting for a lower-cost entry into parallel synthesis workstations."
ReactArray Group Manager Mark Harding added, "Drs Thomas Schwalbe and Keith Simons (VP Business Development, MRSP) are both well known and highly regarded in the market place and we are delighted to be entering into this relationship."
"Greater awareness of ReactArray and new applications will help more scientists in both industry and research organisations understand its capabilities and benefit from the solutions it can provide them."
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019